Black Diamond Therapeutics Share Price (NASDAQ: BDTX)

$2.75

▲

-0.01

(-0.36%)

Live

Last updated on August 19, 2025 at 12:41 AM IST

$₹

Check the interactive Black Diamond Therapeutics Stock chart to analyse performance

Black Diamond Therapeutics stock performance

as on August 19, 2025 at 12:41 AM IST

Today's Low:$2.72
Today's High:$2.78
$2.75
1.09%
Downside
Day's Volatility :2.16%
Upside
1.08%
52 Weeks Low:$1.20
52 Weeks High:$6.75
$2.75
56.55%
Downside
52 Weeks Volatility :82.3%
Upside
59.26%

Black Diamond Therapeutics Stock Returns

Period	Black Diamond Therapeutics	Sector (Health Care)	Index (Russel 2000)
3 Months	30.81%	2.3%	0.0%
6 Months	21.05%	-5.8%	0.0%
1 Year	-52.0%	-10.9%	0.0%
3 Years	-20.0%	2.8%	-11.6%

Black Diamond Therapeutics Key Stats

Check Black Diamond Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.76
Open	$2.79
Today's High	$2.78
Today's Low	$2.72
Market Capitalization	$157.1M
Today's Volume	$693.6K
52 Week High	$6.75
52 Week Low	$1.195
Revenue TTM	$70.0M
EBITDA	$8.0M
Earnings Per Share (EPS)	$0.24
PE Ratio	11.5
Profit Margin	20.63%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	11.85%

Stock Returns calculator for Black Diamond Therapeutics Stock including INR - Dollar returns

The Black Diamond Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Black Diamond Therapeutics investment value today

Current value as on today

₹51,900

Returns

₹48,100

(-48.1%)

Returns from Black Diamond Therapeutics Stock

₹52,174 (-52.17%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Black Diamond Therapeutics Stock

58%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Black Diamond Therapeutics Stock from India on INDmoney has increased by 58% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Black Diamond Therapeutics

Name
Holdings %
Name
Holdings %
T. Rowe Price Investment Management,Inc.
18.48%
Vestal Point Capital LP
9.84%
NEA Management Company, LLC
7.82%
BlackRock Inc
6.10%
Bellevue Group AG
4.81%
Vanguard Group Inc
3.70%

Analyst Recommendation on Black Diamond Therapeutics Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Black Diamond Therapeutics(by analysts ranked 0 to 5 stars)

Black Diamond Therapeutics Share Price Target

What analysts predicted

Upside of 272.73%

Target:

$10.25

Current:

$2.75

Black Diamond Therapeutics share price target is $10.25, a slight Upside of 272.73% compared to current price of $2.75 as per analysts' prediction.

Black Diamond Therapeutics Stock Insights

Price Movement
In the last 7 days, BDTX stock has moved up by 19.5%
BDTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 114.5%
BDTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 126.1%
Price to Sales
ForBDTX every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Black Diamond Therapeutics Technicals Summary

Sell

Neutral

Buy

Black Diamond Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Black Diamond Therapeutics Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Black Diamond Therapeutics	-12.38%	21.05%	-52.0%	-20.0%	-90.86%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Black Diamond Therapeutics	11.5	11.5	NA	0.35	0.12	0.03	NA	2.33
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Black Diamond Therapeutics	Buy	$157.1M	-90.86%	11.5	20.63%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organization	Black Diamond Therapeutics
Employees	24
CEO	Dr. Mark A. Velleca M.D., Ph.D.
Industry	Health Technology

Key Management of Black Diamond Therapeutics

Name	Title
Dr. Mark A. Velleca M.D., Ph.D.	CEO, President & Chairman
Mr. Brent Hatzis-Schoch Esq., J.D.	COO & General Counsel
Dr. Sergey Yurasov M.D., Ph.D.	Chief Medical Officer
Dr. Elizabeth Buck Ph.D.	Co-Founder & Chief Scientific Officer
Ms. Erika Jones	Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
Ms. Melanie Morrison	Chief Development Officer

Important FAQs about investing in BDTX Stock from India :

What is Black Diamond Therapeutics share price today?

Black Diamond Therapeutics share price today is $2.75 as on August 19, 2025 at 12:41 AM IST. Black Diamond Therapeutics share today touched a day high of $2.78 and a low of $2.72.

What is the 52 week high and 52 week low for Black Diamond Therapeutics share?

Black Diamond Therapeutics share touched a 52 week high of $6.75 and a 52 week low of $1.20. Black Diamond Therapeutics stock price today, August 19, 2025 at 12:41 AM IST is trending at $2.75, lower by 59.26% versus the 52 week high.

How to invest in Black Diamond Therapeutics Stock (BDTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Black Diamond Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Black Diamond Therapeutics Shares that will get you 0.5455 shares as per Black Diamond Therapeutics share price of $2.75 per share as on August 19, 2025 at 12:41 AM IST.

What is the minimum amount required to buy Black Diamond Therapeutics Stock (BDTX) from India?

Indian investors can start investing in Black Diamond Therapeutics (BDTX) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Black Diamond Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Black Diamond Therapeutics share’s latest price of $2.75 as on August 19, 2025 at 12:41 AM IST, you will get 3.6364 shares of Black Diamond Therapeutics. Learn more about fractional shares .

What are the returns that Black Diamond Therapeutics has given to Indian investors in the last 5 years?

Black Diamond Therapeutics stock has given -90.86% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?